Latest Syndax News & Updates

See the latest news and media coverage for Syndax. We track all announcements, press releases, and industry mentions in real time, all in one place.

Syndax

Commercial-stage biopharmaceutical company developing and marketing oncology therapies

syndax.com

Headquarters: New York, United States
Company type: Public company
Number of employees: 200–330
Industry: Pharmaceuticals

Last updated October 29

Latest news about Syndax

In short: Syndax halted axatilimab's IPF program after a failed Phase 2 trial and reported Q2 revenue growth.

Company announcements

October 29 Syndax

Syndax shares Q3 clinical data and financials

The company presented updated trial results for SNDX-5613 and axatilimab, highlighting a global partnership with Incyte. It also provided FY2021 operating expense guidance.

October 29 Syndax

Syndax presents Q1 2022 earnings and pipeline progress

The company highlighted financial highlights, including $397.9 million in cash, while outlining pivotal trials for Revumenib and Axatilimab on track for 2023 filings.

October 12 Syndax

Syndax halts axatilimab development in IPF after MAXPIRe trial failure

The Phase 2 trial missed its primary endpoint. Syndax will not pursue further IPF development but continues cGVHD trials with expected results later this year and early 2028.

July 7 Syndax

Syndax highlights late-stage programs and new pipeline assets

The R&D event features SNDX-4321, a novel EGFR inhibitor, and SNDX-62122, a next-generation menin inhibitor, with Phase 2 IPF data expected in 4Q26.

Media coverage

October 29 Northwest Arkansas Home Page

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX

NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors...

October 13 TMCnet

SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syndax Pharmaceuticals...

October 12 MSN

SNDX stock slumps 16% after-hours — what's driving the selloff?

How Did SNDX Retail Traders React? On Stocktwits, retail sentiment around SNDX stayed within neutral territory over the past 2 months, while message volume rose...

October 12 Reuters

Syndax says mid-stage trial of lung disease treatment fails main goal, ends development

Syndax Pharmaceuticals said on Monday it will stop developing a treatment for idiopathic pulmonary f...

Never miss news about Syndax

Track Syndax and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Syndax competitors & trending companies

Browse news for competitors to Syndax and other trending companies.